An important step forward in the field of tumor immunology, was made when CD137+ T-cells were clearly identified as those cells that were terminally differentiated and antigen-specific effector cells, regardless of the antigen specificity [60]. The gene discussed is TNFRSF9; the disease is neoplasm.